← All Coherus Biosciences, INC filings

Coherus Biosciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CHRS
Coherus Biosciences, INC
10-K: Coherus BioSciences Announces 2024 Results, Strategic Shift with UDENYCA Sale
Coherus BioSciences reports 2024 financials and outlines strategic focus on immuno-oncology following planned UDENYCA divestiture.
NASDAQ
CHRS
Coherus Biosciences, INC
10-K: Surface Oncology Enters Exclusive License Agreement with GSK for Development and Commercialization of Novel Immunotherapy
Surface Oncology has granted exclusive worldwide rights to GSK to develop and commercialize a novel immunotherapy, SRF813, targeting the inhibitory receptor CD112R.